Crown Bioscience announced the launch of pre-clinical models of inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) to help inform decision making in pre-clinical drug development.
CrownBio has developed mechanistically diverse models of RA and IBD to drive pre-clinical drug development. The models have been scientifically designed to evoke the similar clinical features observed in humans suffering from these conditions.
The IBD models include, acute dextran sodium sulfate (DSS) challenge and T cell transfer models of IBD, develop symptoms indicative of IBD, including weight loss, colon shortening and an associated inflammation in the gut. While RA models include collagen-induced arthritis and collagen antibody-induced arthritis models that develop the clinical features of arthritis including swollen and inflamed joints.
“Millions of patients endure the pain and discomfort caused by RA and IBD,” said Laurie Heilmann, SVP of Global Strategy, Marketing & Business Development. “Our team led by Joel Tocker, Head of Inflammation, has over 40 years of drug discovery experience in autoimmune and inflammatory diseases to help build ideal models that lead to therapeutic advancements.”